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Background: Titin is a muscle-specific protein found in cardiac and skeletal muscles which is responsible for
restoring passive tension. Levels and functioning of titin have been shown to be affected by cardiac damage.
Due to the inherent difficulty of measuring titin levels in vivo in a clinical setting, we aimed to develop an assay
that could reliably measure fragments of degraded titin in serum and potentially be used in the assessment of
cardiac muscle damage.
Methods: A competitive ELISA was developed to specifically measure levels of the titin sequence 12670’
NVTVEARLIK 12679’, derived by the degradation of titin by matrix metalloproteinase (MMP)-12. Serum samples
from 90 individuals were divided into 3 equally sized groups. One group had been diagnosed with acute
myocardial infarction (AMI) while the remaining two were asymptomatic individuals either with CT-scan signs
of coronary calcium (CT-plusCa) or without coronary calcium (CT-noCa).
Results: Mean geometric levels of the titin fragment in the CT-noCa group were 506.5 ng/ml (±43.88). The CT-plusCa
group showed 50.6% higher levels of the marker [763 ng/ml (±90.14)] (P< 0.05). AMI patients showed 56.3% higher
levels [792 ng/ml (±149)] (P< 0.05).
Conclusions: The titin-12670 fragment is present in both individuals with undiagnosed and diagnosed CVD.
The statistically significant increase in level of the marker in the AMI group is indicative that this neoepitope
biomarker may be a useful serological marker in AMI.
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Titin, also known as connectin, is a sarcomeric protein
expressed in cardiac and skeletal muscle. It is the largest
known protein in nature, with a molecular weight of up
to 3700 kDa [1]. Its main function in the heart is to act
as a long molecular spring by restoring passive tension
during myocardial stretch and enhancing or terminating
active force thus regulating the Frank-Starling mechan-
ism of the heart [2-5]. Distinct passive stress differences* Correspondence: eva@nordicbioscience.com
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reproduction in any medium, provided the orhave been recorded between cardiac and skeletal muscles
[6]. Titin has two isoforms that are co-expressed in the
sarcomere, the N2A which is the larger of the two and is
found in both skeletal and myocardial muscle, and the
N2B isoform which is smaller, stiffer and is found in
cardiac muscle [1,7-12]. Due to the different stiffness in
titin’s isoforms, it has been proposed that the adaptive
or maladaptive ratio alteration between the two iso-
forms could affect its myocardial contractile properties
[4,7,13-17]. Isoform modifications and ratio alterations
were first described in animal models while clinical stud-
ies have also reported isoform changes during dilated
cardiomyopathy (DCM), aortic stenosis (AS), diastolic
heart failure (DHF) and ischemic heart disease (IHD)ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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the methods for detecting and quantifying titin levels.
The studies rely on invasive tissue extractions which are
then analysed by methods such as immunoblotting and
gel electrophoresis.
Extracellular matrix (ECM) components are degraded
by a number of different proteases including matrix
metalloproteinases (MMPs). MMP-degradation of pro-
teins generates specific cleavage sites on fragments
which in turn enable the development of new epitopes.
Our group previously discussed neoepitopes that may
have potential utility as biomarkers of unbalanced ECM
remodeling in a number of different pathologies and can
be measured in biological fluids such as serum, plasma
and urine [22-27]. Key benefits of measuring biomarkers
in body fluids are that this process is non-invasive and,
because the specific neoepitopes represent a unique ‘fin-
gerprint’ of the proteolytic cleavage of the protein, they
identify the specific tissue being turned over and also
detect whether the tissue is diseased or healthy. Since
pathology-related cardiac remodeling is initiated before
clinical onset and appearance of any symptoms [28],
biomarkers that indicate abnormal remodeling could be
utilised for early diagnosis of cardiovascular disease
(CVD). The cardiac-specific markers troponin I and T
(cTnI & cTnT) are already used to closely monitor myo-
cardial damage and related pathological events [29-33].
Titin has been previously shown to be degraded by
MMP-2 localised in the Z-disk of the cardiac sarcomere
[34,35]. However to our knowledge no biomarkers based
on titin-relevant neoepitopes resulting from the degrad-
ation activity of either MMP-2 or other metalloprotei-
nases have been described.
During digestion of human tissue by an array of
exogenous metalloproteinases, a large number of proteo-
lyzed peptides have been identified using mass spec-
trometry [36]. Among these, a titin specific fragment
12670’ NVTVEARLIK 12679’ was identified to have
been cleaved specifically by MMP-12. Proteomic analysis
revealed that the sequence is located in the IG domain
within the distal tandem IG segment and is homologous
only in humans and mice. Even though at least in mur-
ine models MMPs and MMP-12 in particular have been
implicated in cardiovascular events such as atherogenen-
esis [37], the only MMP previously described to have a
direct effect on titin degradation is MMP-2, which con-
tributes to titin degradation in ischemic and reperfusion-
related events [34,37].
We hypothesized that the MMP-12 specific fragment
of titin could be potentially useful for monitoring patho-
logic cardiovascular events and thus as a biomarker.
Our hypothesis was that titin degradation fragments
may be released and found in the circulation, in a similar
way as adjacent proteins in the myocyte, such astroponin, are released and measured, and that the level of
titin fragments may be associated to the degree of myo-
cyte damage. Examples of cardiac markers based on
troponin, a protein which is in close proximity to and
interacts with titin, indicate that release of myocyte-
related protein remodeling fragments into the circulation
can provide accurate markers of pathology-related remod-
eling. We investigated this hypothesis by developing a
monoclonal antibody and a serum-based assay for the
identification of the titin fragment degenerated specifically
by MMP-12. We used the assay in three well- charac-
terised populations with different degrees of heart disease,
but with comparable gender- and age-composition. The
samples were collected by the same hospital staff using
standard procedures, hence adding low biological variance
and increased clinical significance.
Methods
Reagents
All reagents used for experiments were standard high-
quality chemicals from Merck (Whitehouse Station, NJ,
USA) and Sigma Aldrich (St. Louis, MO, USA). The syn-
thetic peptides used for monoclonal antibody production
were purchased from the Chinese Peptide Company,
Beijing, China.
Selection of the peptide for immunization
The amino acid sequence selected for the assay was
chosen from mass spectrometry performed on human
tissue [36]. Peptide fragments were identified using the
Uniprot database, with the accession number C0JYZ2.
The sequence NVTVEARLIK located between amino
acid position 12670’ and 12679’ (titin) was selected as
the immunogen. The first 10 amino acids of each free
end of the sequences identified were regarded as a target
sequence. All relevant sequences were analyzed for hom-
ology and then blasted for homology using the NPS@:
network protein sequence analysis [38]. The sequence
was identified by Uniprot and PBIL (Pole Bio Informa-
tique Lyonnais) network protein sequence analysis in
UNIPROT-SWISSPROT databases and was found to be
unique to human and mouse titin. The full 10- amino
acid sequence was also blasted with 1 and 2 mismatched
amino acids as well as with 95%, 90%, 85%, 80%, 75%,
70% similarity levels. In all cases the 10 amino acid
sequence was found to be unique for human and mouse
titin. The selected sequence was also found to be present
in 6 out of 8 titin isoforms produced by alternative splicing.
These were isoforms 3 (small cardiac N2B), 7 (cardiac
novex-2) and 8 (cardiac novex-1) that are known to be
present in cardiac muscle (Uniprot accession numbers
Q8WZ42-3, Q8WZ42-7 and Q8WZ42-8 respectively)
and isoforms 2, 4 and 5 (Uniprot accession numbers
Q8WZ42-2, Q8WZ42-4 and Q8WZ42-5 respectively) [39].
Vassiliadis et al. Journal of Translational Medicine 2012, 10:140 Page 3 of 10
http://www.translational-medicine.com/content/10/1/140The 6 amino acids from the C terminal end of the
selected peptide (12675’ EARLIK 12679’) were also
blasted using NPS to assess and identify the sequence
similarity with potential cross-reactive sequences found
in the circulation. This only revealed a similarity with a
sequence found in sterile, alpha motif domain-
containing protein, while the remaining hits were found
to be titin-specific.Immunization procedure
Six 4–6 week old Balb/C mice were immunized subcuta-
neously in the abdomen with 200μL emulsified antigen
(50 μg per immunization), using Freund’s incomplete
adjuvant (KLH-NVTVEARLIK). Immunizations were
performed at two-week intervals until stable titre levels
were obtained. At each bleeding, the serum antibody
titre was measured and the mice with the highest anti-
body titre and best reactivity towards serum and urine
were selected for fusion. The selected mice were boosted
intravenously with 50 μg immunogen in 100μL 0.9%
sodium chloride solution three days before surgical
removal of the spleen for cell fusion. The study was
approved by the Beijing laboratory animal administration
office under approval number 200911250.Fusion and antibody screening
The fusion procedure has been described elsewhere [40].
Briefly, mouse spleen cells were fused with SP2/0 mye-
loma fusion partner cells. The hybridoma cells were
cloned using a limiting dilution method and transferred
into 96-well microtiter plates for further growth. Standard
limiting dilution was used to promote monoclonal growth.
Supernatants were screened using an indirect ELISA,
while the biotinylated peptide Biotin-NVTVEARLIK was
used as a catcher peptide on streptavidin-coated micro-
titre plates.Characterization of clones
Native reactivity and peptide-binding of the monoclonal
antibodies in human serum was evaluated using a pre-
liminary ELISA with a 10 ng/mL biotinylated peptide
coater on a streptavidin-coated microtitre plate and the
supernatant from the growing monoclonal hybridoma.
Clone specificity was tested against a free synthetic pep-
tide (NVTVEARLIK) and a non-sense synthetic peptide
sequence. Isotyping of the monoclonal antibodies was
performed using the Clonotyping System-HRP kit,
cat.5300-05 (Southern Biotech, Birmingham, AL, USA).
The selected clones were purified using Protein G columns
according to the manufacturer’s instructions and dialysed
(GE Healthcare Life Science, Little Chalfont, Bucking-
hamshire, UK).MMP-12 titin assay protocol
The following competitive ELISA protocol was opti-
mised for use with the MMP-12 titin monoclonal anti-
body. The selected monoclonal antibodies were labelled
with horseradish peroxidase (HRP) using the Lightning-
Link Horseradish Peroxidase (HRP) antibody labelling
kit according to the manufacturer’s instructions (Innova-
bioscience, Babraham, Cambridge, UK). A 96-well strep-
tavidin plate (Roche Diagnostics, Basel, Switzerland) was
coated with 1.3 ng of the biotinylated synthetic peptide,
Biotin-CGG-NVTVEARLIK, dissolved in assay buffer
50 mM Tris BTB (p.H 8 at 20°C) and incubated for
30 minutes at 20°C. 20μL of the peptide calibrator
or sample were added to appropriate wells, followed by
100 μL of 40 ng/ml conjugated monoclonal antibody,
and incubated for 1 hour at 4°C. Finally, 100 μL tetra-
methyl benzinidine (TMB) (Kem-En-Tec cat.438OH,
Taastrup, Denmark) was added, and the plate was incu-
bated for 15 minutes at 20°C in the dark. All of the
above incubation steps included shaking at 300 rpm.
After each incubation step the plate was washed five
times in washing buffer (20 mM Tris, 50 mM NaCl, pH
7.2). The TMB reaction was stopped by adding 100- μL
of stopping solution (1% HCl) and measured at 450 nm
with 650 nm as the reference. A calibration curve was
plotted using a 4-parametric mathematical fit model
with a starting concentration of 1000 ng for the standard
peptide following a 2-fold dilution.Technical evaluation
From 2-fold dilutions of human serum, linearity was
calculated as a percentage of recovery of the 100% sam-
ple. The lower limit of detection (LLD) was determined
from 21 zero samples (i.e. buffer) and calculated as the
mean + 3x standard deviations. The inter- and intra-
assay variation was determined by 10 independent runs
of six quality control (QC) human serum and mouse
heparin plasma samples run in duplicate.Tissue specificity
Cardiac and skeletal muscle where collected from an
adult mouse and frozen in liquid nitrogen. Mouse tissue
was selected for the specificity test because of the 100%
homology of the selected antibody sequence between
human and mouse, and because of the lack of available
human tissue samples for both cardiac and correspond-
ing skeletal tissue. Titin was extracted according to the
method described by Granzier and Irving [6]. Briefly, the
tissues were pulverized to a fine powder using a mortar
and a pestle bathed in liquid nitrogen, and then rapidly
added to 9 volumes of hot solubilization buffer (50 mM
Tris–HCl, 2% SDS, 10% glycerol, 80 mM DTT) and
homogenized for 90 seconds in a 90-95°C water bath.
Table 1 Demographics of each group in the study, mean
values and standard deviation
CT-noCa CT-plusCa AMI ANOVA
n=30 n=30 n=30 p-value
Age (yrs.) 60.2 60.3 64.5** 0.001
[59.8; 60.7] [60.0; 60.6] [56.0; 73.0]
TriglyceridesA
(mmol/L)
1.57 1.49 1.30 0.52
[0.85; 2.93] [1.00; 2.21] [0.78; 2.19]
HDL CholesterolA
(mmol/L)
1.28 1.36 1.13 0.07
[0.93; 1.75] [0.98; 1.89] [0.83; 1.52]
LDL Cholesterol
(mmol/L)
3.14 3.26 2.93 0.47
[2.13; 4.16] [2.29; 4.22] [1.74; 4.11]
Total Cholesterol
(mmol/L)
5.25 5.47 4.74 0.07
[4.06; 6.43] [4.29; 6.64] [3.44; 6.04]
Systolic Blood
Pressure (mm Hg)
145 147 159* 0.03
[131; 159] [128; 167] [132; 187]
Diastolic Blood
Pressure (mm Hg)
86 85 88 0.80
[76; 95] [75; 96] [72; 103]
Agatston score - 1299 - -
[717; 2352]
HeartscoreA 5.29 6.38 8.00 0.07
[2.89; 9.68] [2.96; 13.7] [4.01; 16.0]
OsteopontinA 83 99 111 0.08
[52; 132] [67; 145] [61; 201]
OsteoprotegerinA 1583 1704 2170** 0.0007
[1144; 2189] [1335; 2175] [1487; 3168]
FibulinA 63 63 78** 0.0006
[49; 80] [50; 80] [62; 99]
CT-noCa: Asymptomatic individuals without detectable coronary calcium;
CT-plusCa: Asymptomatic CVD with high coronary calcium; AMI (Acute
Myocardial Infarction): patients with NSTEMI-ACS. Mean values [+/− STD)],
A Geometric mean values [+/− STD)], and p-value from one-way of analysis of
variance (ANOVA). The level of significance of p-values from comparison of
each group against the control group ‘CT-noCa‘was adjusted for multiple
comparisons by the method of Dunnet (*: p< 0.05; **: p< 0.01; ***: p< 0.001).
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down and stored at −20°C.
A buffer exchange was performed using Vivaspin-2
3000 MWCO PES columns (Sartorius Stedim Biotech,
Goettingen, Germany) against PBS 1X and the protein
concentration was measured using the NanoDrop ND-
1000 spectrophotometer (Thermo Scientific, Waltham,
Massachusetts, USA). MMP-12 derived titin fragments
were measured in the extracted samples using the ELISA
assay described above.
Patients and sample collection
Patients
As described in detail below, our study is a case–control
study, in which we selected and grouped individuals on
the basis of prior knowledge about the presence or ab-
sence of well-defined manifestations of ischemic heart
disease. The groups were chosen for the sole purpose of
investigating connections between biomarkers and dif-
ferences in the degree or type of ischemic heart disease.
Individuals from larger ongoing studies were selected to
ensure this analysis compared populations with a similar
gender- and age- distribution. Importantly, pre-analytical
conditions were similar in all groups.
Ninety individuals with different degrees of atheros-
clerotic heart disease, were selected from larger studies
(DANRISK and DEFAMI), which were actively enrolling
patients at Odense University Hospital in Denmark during
the same time period. The individuals were divided into
three groups of 30. One group consisted of subjects with-
out previous CVD and no coronary calcium detectable on
a CT scan (CT-noCa); another 30 asymptomatic subjects
from the DANRISK study had no previous CVD but were
diagnosed with subclinical CVD due to their severe sub-
clinical coronary calcium shown on CT scans (CT-plusCa);
and the remaining 30 patients had acute AMI, and were
from the DEFAMI study (Table 1). All samples from these
individuals were pre-analytically handled and stored by the
analytical unit at Odense University Hospital.
In the DANRISK-study [41], a random sample of 1825
middle–aged men and women was in 2009 invited for
screening for coronary disease. Screening included a car-
diac CT scan, followed by an estimation of the amount
of coronary calcium using the Agatston score. Of the
invited subjects, 1257 were considered for inclusion in
the study. From this group were excluded those with
prior ischemic heart disease or diabetes mellitus (n= 100),
leaving a total of 1157 patients for analysis. Among
the individuals aged 60 years (n= 647), we selected
30 patients without coronary calcium (CT-noCa) and
another 30 with an Agatston score ≥400 (CT-plusCa).
In the DEFAMI-study, all patients admitted between
October 1 2009 and April 30 2010 at any clinical depart-
ment at Odense University Hospital and having troponinanalysis performed because of suspected acute coronary
syndrome were enrolled. Blood sampling was done as
part of a large Biobank within the first 24 hours of
symptom onset. Of the 822 patients in the DEFAMI
study, 30 individuals with non-ST elevation myocardial
infarction (NSTEMI, n = 24) or unstable angina (n = 6)
were selected to participate in the current study. Their
age was approximately 60 years and their gender distri-
bution matched the two above-mentioned DANRISK
subgroups. NSTEMI was defined as increased TnI levels
above 0.03 μg/l, but ECG without ST-elevations.
Unstable angina was defined as chest pain occurring
during rest or minimal physical exertion. The mean TnI
level in the NSTEMI-ACS group was 0.62 μg/l (range
0.01-5.23 μg/l). The NSTEMI-ACS patient group was
chosen because in these patients it was possible to
Figure 1 Specificity of the antibody to the selection peptide vs.
non-reactivity to the elongated peptide. (A) The signal was
assessed as the optical density at 450 nm, subtracting the
background at 650 nm, as a function of peptide concentration. LLD
was found to be 5.43. Point zero represents increased signal
inhibition and therefore elevated levels of the epitope in serum.
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other interventions for acute myocardial infarction,
which could interfere with biochemical assays.
In these three patient groups, hypertension was
defined as the use of antihypertensive medical treatment
and diabetes as the use of anti-diabetic medication. The
patients were considered to have hypercholesterolemia if
the diagnosis was stated in the patient file or if the pa-
tient was taking cholesterol-lowering treatment.
Systolic and diastolic blood pressure was measured on
the same day as blood sampling. Agatston score was cal-
culated in the two groups of patients undergoing cardiac
CT. Troponin in the NSTEMI-ACS group was measured
prior to the blood sampling. Total cholesterol, LDL,
HDL and triglycerides were measured prior to the blood
sampling. Blood samples were drawn in tubes with
EDTA and centrifuged at 200 g for 10 min. Plasma was
stored at −80°C until biochemical analysis.
Protocols for all three studies at Odense University
Hospital were approved by the Regional Ethics Commit-
tee before the initiation of the trials. Informed consent
was obtained from all participating patients.
Statistical analysis
The data of HDL cholesterol, heartscore, the ratio be-
tween LDL and HDL cholesterol, and levels of HDL trigly-
cerides, osteoprotegrin (OPG), fibulin, osteopontin (OPN)
and titin were logarithmically transformed to obtain sym-
metry of variance. One-way analysis of variance (ANOVA)
was used for comparison among groups. If ANOVA
revealed a statistically significant difference between
groups, each of the groups (CT-plusCa and AMI) was
compared with the control group (CT-noCa) with the
level of significance adjusted for multiple comparisons by
the method of Dunnet. For each group of CT-plusCa and
AMI, the markers showing a statistically significant differ-
ence between groups in the ANOVA were further investi-
gated by ROC curve against the CT-noCa group.
The relationship between titin and other factors (tri-
glycerides, LDL-cholesterol, HDL-cholesterol, total chol-
esterol, systolic blood pressure, diastolic blood pressure,
and age) was investigated by univariate linear regression
analysis and multivariate analysis of variance using the
general linear model procedure. The diagnostic value of
the assay was calculated by receiver-operating character-
istic (ROC) curve plots.
The Statistical Analysis System (SAS Institute, Cary,
NC, USA) was used for the analyses. The level chosen to
indicate statistical significance was 5%.
Results
Demographics
Key demographic information and biochemical measure-
ments are presented in Table 1.Clone characterization & tissue specificity
The clone selected for ELISA development was determined
to be the IgG1 subtype. The native reaction of this clone
was high against human serum. The clone was found
to react specifically to the target sequence and not the
elongated peptide (Figure 1). The clone showed higher
signal inhibition towards mouse cardiac muscle (51%
inhibition) than to skeletal mouse extracts (21% inhibition).
Technical evaluation
The typical standard curve is presented in Figure 1,
showing a 4-parametric fit for the assay. The lower limit
of detection for the assay was 9.78 ng/mL. Dilution
recovery was found to be within 100 ± 15%. The inter-
and intra-assay variation was found to be 4.33 and
5.49% respectively.
Clinical cohort
A statistically significant increase in the marker was
measured in CT-plusCa and AMI patient groups
(Table 2). The geometric mean level of the MMP-12
degraded titin fragment in the CT-noCa group was
506.5 ng/ml. In the AMI patient group, the mean
value was 792 ng/ml (56.3% increase, P< 0.05), and in
the CT-plusCa group 763 ng/ml (±90.14) (43% increase,
Table 2 Comparison of levels of MMP-12-generated
fragments of titin in the clinical cohort
CT-noCa CT-plusCa AMI
n= 30 n= 30 n= 30
Geometric mean value(ng/ml) 506.5 759.7 792.5
SEM 43.88 90.14 149.5
% Increase Control 43% 56.3%
P Value Control 0.03 0.02
Table 3 ROC values of the assay measuring MMP-12
generated titin fragments, vs. other known cardiac markers
CT-noCa Vs. CT-plusCa Vs. AMI
Systolic Blood Pressure 0.54 0.70 **
Total Cholesterol 0.55 0.61
LDL 0.53 0.55
Heart score 0.57 0.70 **
Osteoprotegerin 0.58 0.73 ***
Fibulin-1 0.49 0.74 ***
Osteopontin 0.64 * 0.64 *
MMP12-Titin 0.69 ** 0.65 *
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geneity of variance was non-significant (p = 0.07) there
was a tendency to higher variance in the CT-plusCa
group (standard deviation 74%); AMI (standard devi-
ation 97%) as compared with the CT-noCa group (stand-
ard deviation 54%).
The highest sensitivity and specificity of the assay was
found at the cut-off value of 545 ng/ml. At this value the
sensitivity and specificity were 73.3% and 63.3% respect-
ively for the CT-plusCa group, while the positive pre-
dictive value (PPV) and negative predictive value (NPV)
were 64.7% and 68% respectively. In the AMI group,
sensitivity and specificity was 67.7% and 63.3% respect-
ively, while the PPV and NPV were 65.6% and 65%.
ROC values of the assay
The assay was found to have a highly significant ROC
value for all patient groups (Table 3).Figure 2 MMP-12 generated fragments of titin measured in a
clinical cohort consisting of individuals with no diagnosed
cardiac pathology and no coronary calcium. (CT-noCa) (n = 30),
with high coronary calcium (CT-plusCa, n = 30), acute myocardial
infarction (AMI, n = 30). A statistically significant difference between
the groups was measured by one- way ANOVA (P< 0.05). The bar
shows geometric mean value.Relationship between titin and other factors
The marker showed no significant correlation with
any other physiological measurements. The relationship
between titin and the physiological characteristics of tri-
glycerides, LDL-cholesterol, HDL-cholesterol, total chol-
esterol, systolic blood pressure, diastolic blood pressure,
and age was statistically non-significant both in the
separate univariate linear regression analysis and in
multivariate analysis of variance (Wilks Lambda criteria:
CT-noCa: p = 0.79.; CT-plusCa: p = 0.39; AMI: p = 0.74).
The level of titin in the AMI patients also showed no
significant correlation with the troponin I levels.
Discussion
The study relied on a well-characterised cohort in which
all samples were collected under the same standard
operating procedures. The study presents for the first
time an assay for in vivo detection of titin degradation
fragments that have been associated with abnormal
remodeling and cardiac damage. The assay had a good
native reactivity in human serum and was technically
robust with acceptable inter- and intra-assay variation,
dilution recovery and a low limit of detection. The assay
detected statistically significant increased levels of the
biomarker in all the pathology-related clinical cohorts
when compared with non-diseased individuals. The
assay has shown increased and statistically significant
ROC values for all cohorts. Unlike all but one of the
other known cardiac markers measured in the cohorts,
the titin degradation marker showed a statistically sig-
nificant elevation with high ROC values in the CT-
plusCa and AMI groups (Table 3). With the exception of
osteopontin, no other marker showed a high ROC and
significant p-value in the group of CVD asymptomatic
individuals with increased coronary calcium levels (CT-
plusCa). We believe that the raised titin levels may be a
tissue-specific indication of the underlying remodeling
processes occurring in the myocyte prior to injury and
during pathology development which could be of add-
itional value for early diagnosis of CVD asymptomatic
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ment of the MMP-12 titin marker at a later time point
in the development of CVD could be of great value to
determine the validity of this hypothesis.
The statistically significant increase in the marker
levels in the AMI group may be related to the increased
macrophage levels found following AMI at the injury
site. Macrophages are implicated in all components of
AMI response, which include inflammation, scar forma-
tion and remodeling [42]. As will be discussed later,
macrophages are the main source of MMP-12 in adult
tissue which participates in inflammatory processes and
ECMR. Hence, increased levels of MMP-12 or other
macrophage-derived proteases acting on the infarcted
myocardium may be responsible for protease-driven myo-
cardial remodeling. The raised MMP-12 levels are thought
to increase degradation of titin at the site of injury, with
the titin fragments indicating myocardial injury.
The marker was found not to be correlated with age,
LDL, HDL, total cholesterol, triglycerides, BT systolic or
diastolic pressure levels which implies that the titin frag-
ment levels are independent of these markers. The lack of
correlation may be also attributed to the fact that this assay
measures an MMP-degraded fragment of titin and not total
protein, as do tests for the above-mentioned biochemical
measurements. We believe that the fact that the marker
does not directly correlate with the above measurements is
not alarming, because the specific titin marker does not
measure total protein levels as the above measurements
but rather the increased titin degradation levels which
results from chronic abnormal remodeling. Further valid-
ation of this finding in additional, larger clinical cohorts,
could potentially validate this titin marker’s utilisation in
clinical prediction models as an additional independent risk
factor to diagnose asymptomatic patients. The marker
should be further evaluated for all criteria set for novel car-
diovascular risk factors which include its reliability, sensi-
tivity, availability/practicality, clinical significance and value
of independent information on prognosis [43,44].
To date there is no adequate relevant literature regard-
ing the specific activity of MMP-12 – a human macro-
phage elastase - and its effect on cardiac remodeling
during either physiology or pathology. Human and animal
studies have established the presence and activity of
MMPs such as −2, -9 and −7 on cardiac-related remodel-
ing [37,45-52]. Whether the acknowledged MMP-driven
activity is dependent on tissue inhibitors of metalloprotei-
nases (TIMPs) or not remains unclear [53]. Even though
there is evidence of MMP-12 activity in cardiovascular
pathologies such as aortic aneurysms and atherosclerosis
[54-58], to our knowledge there is no pre-existing evi-
dence directly implicating MMP-12 activity in cardiac
remodeling. The main MMP-12 source in adult tissue is
macrophages which have been reported to be an activeparticipant in inflammatory processes and vascular extra-
cellular matrix remodeling [59]. The role of MMP-12 in
cardiac pathology is not well understood. Benoit et al.
showed that MMP-12 expression was increased in cardiac
valves taken from patients suffering from infective endo-
carditis [60].
Biochemical markers consisting of protein fragments
from matrix remodeling degradation may be informative
of disease pathology and progression, which in turn may
be useful for diagnostic and prognostic purposes. These
markers could potentially detect changes resulting from
intervention strategies and serve as surrogate markers of
drug efficacy [61]. The continuous search and utilisation
of cardiac specific markers such as cTnI & cTnT, that
can provide additional information, could be of real clin-
ical value for improved patient care by aiding an early
diagnosis, prognosis risk stratification, therapy selection
and close monitoring of patients [29]. The described
fragment of titin should be further evaluated in add-
itional clinical cohorts in a longitudinal study in which
other cardiac markers such as cTnI & cTnT will also be
measured in order to facilitate its categorisation accord-
ing to the BIPED criteria [22].
The main limitations of this study include the absence
of direct quantitative measurements of MMP-12 and
other relevant protease levels in the tissue from the clin-
ical cohorts and thus a correlation between the levels of
the titin fragment and MMP-12 activity. It should also
be noted that we selected and grouped individuals on
the basis of knowledge about the presence or absence of
well-defined manifestations of ischemic heart disease
and to match the groups for age- and gender distribu-
tions. However, it is important to note that each group
does not necessary reflect all patients with this disease,
for example the AMI group, which only included non-
STEMI patients. Additionally, the study lacked a detailed
assessment of the troponin C and I levels in all patients.
Due to their position in the myocyte and their vicinity to
the titin location, troponin C and I could have been
tested for their correlation to titin. A further limitation
is that even though the described fragment is derived
from MMP-12 activity in vitro, other proteases or a
combination of proteases could potentially generate this
fragment in vivo. The fragment’s specificity for cardiac
tissue was evaluated in mouse tissue, due to the
sequence homology between human and mouse, but in
future an assessment in human tissue could provide
more clinically reliable information. Due to the presence
of titin in both skeletal and cardiac muscle, measure-
ment of the marker in other pathologies such as muscu-
lar dystrophies could indicate a broader use for this
marker. The study also lacks immunohistochemistry and
western blot data due to the lack of tissue from the en-
rolled patients. Despite numerous attempts to obtain
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the clone currently used could not be utilised for west-
ern blot use. Additional clones are being raised by new
immunisations that could produce a clone that can be
used for western blotting and immunohistochemistry.
Even though the marker can be accurately measured in
serum, it may be also present in other body fluids such
as urine and saliva. These have not been assessed in this
study due to lack of relevant material. However, when
the material is made available it will be assessed accord-
ingly. This will allow for additional assessment of the
marker and the influence of renal function on its pres-
ence and levels. Measurement of the marker in a larger
cohort and with additional CVD related pathologies
will also allow for a better description of the marker.
Measurement of additional biomarkers such as tro-
ponins and CKMB and direct comparisons of these
with MMP-12 generated titin fragments will add to our
understanding of the marker and its potential utility.
Finally, even though the marker was found to be elevated
in the tested clinical groups, the result represents only a
“snapshot” in the complex cardiac remodeling process
that occurs during pathologic events. A longitudinal
study including detailed monitoring of the marker during
cardiac remodeling is needed to better describe the mar-
ker, together with further assay optimisation.
Conclusion
We have developed and validated a serum-based competi-
tive assay using a specific monoclonal antibody for the
detection of the titin sequence, titin-12670 (NVTVEARLIK).
To our knowledge this is the first neoepitope biomarker
that specifically detects in serum, in vivo, titin remodel-
ing activity and is related to cardiac damage in the
cohorts examined in this study. The data suggest that
there is a promising potential for the use of such biomar-
kers to assesscardiovascular related diseases in a clinical
setting. Further testing in additional cohorts is required
to validate our findings.
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